The race to increase human life span through biotech just got tighter.
Retro Biosciences, the AI-powered company whose mission is to develop therapies that reverse age-related disease, has just announced it's in the process of a $1 billion round of funding toward that goal. It will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment that’s set to enter an early-stage trial in Australia this year.
